today announced positive topline results from the Phase 2 study evaluating itolizumab in the treatment of moderate to severe ulcerative colitis (UC). As the U.S. market looks to rebound from a ...
After hours: March 14 at 5:28:20 PM EDT Loading Chart for EQ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback